This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

NeoStem's Subsidiary, PCT, Adds Key Personnel: Robert Shaw, Vice President Of Commercial Sales, And Brian Hampson, Senior Director, Engineering And Innovation

ALLENDALE, N.J., Aug. 12, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("the Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today the addition of two new leaders to the PCT team-Robert ("Bob") Shaw as Vice President of Commercial Sales, and Brian Hampson, as Senior Director, Engineering and Innovation.

Mr. Shaw will be tasked with bolstering the Company's top line revenue growth through strategic transactions and additional business lines, as well growing the existing client base through enhanced technical sales and marketing initiatives.

Mr. Hampson will be heading up a new department at PCT, Engineering and Innovation, created as a formalization of PCT's ongoing engineering and process development programs. This department will accelerate PCT's efforts to address the important issues of scale up, automation, integration, and improved robustness within the regenerative medicine industry.

"It gives me great pleasure to bring these experts onto the PCT team," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. "Bob brings a wealth of experience in cell therapy industry sales as well as a proven track record of meeting and exceeding business development goals, and Brian's expertise will help us refine and advance development, manufacturing processes and capabilities within our company."

"We are proud of our 29% revenue growth in Q2 2013 over the same period in 2012 and look to continue this strong growth trend with the addition of Bob Shaw to our management team," said Robin L. Smith, MD, Chairman and CEO of NeoStem. "We are confident that PCT's position as an industry-leader will benefit significantly from the technical expertise, industry contacts and vast product development experience Brian will bring to bear."

Over the last two decades Mr. Shaw has held several positions at EMD Millipore Corporation, a top tier supplier to the life science industry. Most recently, he held the position of Commercial Director – Stem Cell Initiative where he was responsible for strategic and technical leadership, including all aspects of product marketing, product development and commercial management. He previously held the position of Director of Strategic Marketing and World Wide Training Program Director for Vaccines and Emerging Biotech, where he had responsibility for management and development of vaccines and emerging biotech markets across the world, and the position of Program Director, Aseptic Processing, where he had global responsibility for a $300 million business. Mr. Shaw earned an M.B.A. from Loyola College, Maryland, and an M.S in Viral Immunology, University of Toronto. Mr. Shaw serves as a Board member of the Alliance for Regenerative Medicine, where he is also Co-Chair, Operations and Governance Committee. He was previously the Founder and Co-Chair, Process Development Committee for the Massachusetts Biotechnology Council, and has held positions on the Boards of the Westford Education Foundation and the Parenteral Drug Foundation, and serves on the Editorial Advisory Board of BioProcess International.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,218.40 -70.23 -0.38%
S&P 500 2,106.80 -10.59 -0.50%
NASDAQ 4,976.9260 -31.17 -0.62%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs